Authored By: Sarah
11 Jul 2024

 Antinuclear Antibody Test Market Size to grow by USD 392 million between 2024-2028

According to a research report “ Antinuclear Antibody Test Market” by End-user (Hospitals, Clinical diagnostic laboratories) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 392 million, at a CAGR of  7.08% during the forecast period. The Antinuclear Antibody (ANA) test is a crucial diagnostic tool in identifying autoimmune disorders, such as rheumatoid arthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, and others. This blood test detects the presence of antinuclear antibodies produced by the immune system, which bind to the body's own tissues. The market for ANA tests is experiencing significant growth due to the increasing prevalence of autoimmune diseases. According to the Foundation for Peripheral Neuropathy, Guillain-Barre Syndrome (GBS) affects approximately 3,000-6,000 individuals in the US annually, creating a larger target population for early screening and effective treatment. This expanding patient base is expected to fuel the demand for ANA testing in the healthcare industry.

Browse market data tables, figures, and in-depth TOC on “Antinuclear Antibody Test Market” by End-user (Hospitals, Clinical diagnostic laboratories) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By End-user, the Hospitals segment is projected to dominate the market size in 2024

ai_market_segmentation_by

By Geography, North America  segment is expected to hold the largest market size for the year 2024

The Antinuclear Antibody (ANA) Test Market represents a significant opportunity for industry players due to the increasing prevalence of autoimmune diseases. This diagnostic test is crucial for identifying various autoimmune disorders, including systemic lupus erythematosus and rheumatoid arthritis. Market growth is driven by rising disease incidences, technological advancements, and growing healthcare expenditures. Key players in this market focus on product innovation, strategic collaborations, and expanding their geographical presence to capitalize on these trends.

North America is forecasted to hold the largest market size by region in 2024

The Antinuclear Antibody (ANA) Test Market represents a significant growth opportunity for diagnostic companies due to the rising prevalence of autoimmune diseases. This market is driven by increasing awareness and early diagnosis of autoimmune disorders, technological advancements in testing methods, and expanding healthcare infrastructure. Key players in this market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, and DiaSorin S.p.A, among others. These companies invest in research and development to offer innovative solutions and maintain their competitive edge.

The Antinuclear Antibody Test Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Abbott Laboratories
  • Abcam plc
  • Antibodies Inc.
  • Bio Rad Laboratories Inc.
  • BioVision Inc.
  • Grifols SA
  • Immuno Concepts Ltd.
  • Merck KGaA
  • Orgentec Diagnostika GmbH
  • Perkin Elmer Inc.
  • Quidelortho Corp.
  • Seramun Diagnostica GmbH
  • Thermo Fisher Scientific Inc.
  • Transasia Bio Medicals Ltd.
  • Trinity Biotech Plc
  • Werfenlife SA
  • ZEUS Scientific Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Antinuclear Antibody (ANA) test market is witnessing significant growth due to the increasing prevalence of autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). The market for ANA tests is driven by the development of disposable cartridges and rapid test results, making diagnosis more accessible in clinical laboratories and hospitals. Autoantibodies, including those associated with RA (RA-ANA), SLE (SLE-ANA), and other diseases like Autoimmune Hemolytic Anemia (AIHA), FANA, and Autoimmune Hepatitis (AIH), are detected using various techniques such as homogenous pattern, speckled pattern, and nucleolar pattern in immunofluorescence assays. The gold standard for ANA testing is immunofluorescence, but enzyme-linked immunosorbent assays (ELISA) and multiplex assays are gaining popularity due to their ease of use and cost-effectiveness. Developing economies face a lack of awareness and limited reimbursement policies, which may hinder market growth. New variants of autoantibodies, such as those associated with motor axonal neuropathy, are being discovered, necessitating the development of new diagnostic assays. The prognostic value of ANA tests in diseases like SLE and RA is a topic of ongoing research, as is the role of ANA tests in the diagnosis of diseases like Guillain-Barré Syndrome (GBS) and diseases associated with systemic autoantibodies. Recent studies published on MedRxiv and Arthritis Research have highlighted the importance of ANA tests in the diagnosis and management of autoimmune diseases. The healthcare system's role in facilitating access to ANA testing and treatment options is crucial in improving patient outcomes. The NCBI database provides valuable information on ANA testing and related diseases.

Market Research Overview

The Antinuclear Antibody (ANA) test market is witnessing significant growth due to the increasing prevalence of autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). Disposable cartridges for ANA testing are gaining popularity due to their ease of use and rapid test results. The gold standard for ANA testing is immunofluorescence, which can detect autoantibodies in a homogenous pattern (HA), speckled pattern (SP), or nucleolar pattern (NP). RA and SLE are associated with various autoantibodies, including those against double-stranded DNA, Sm, RNP, and Ro/La. Diagnostic assays such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assay (IFA) are used for ANA testing. Developing economies face a lack of awareness and limited reimbursement policies, which hinder the growth of the ANA testing market. Autoimmune hepatitis (AIHA), drug-induced lupus, mixed connective tissue disease, polymyositis, Raynaud’s Syndrome, scleroderma, and other autoimmune diseases are also diagnosed using ANA testing. New variants of autoantibodies and systems, such as anti-centromere, anti-histone, and anti-nucleolar autoantibodies, are being discovered, leading to the development of new diagnostic assays and reagents. The ANA testing market is expected to grow due to the increasing number of hospitals and clinical laboratories offering ANA testing services. The market is also driven by the prognostic value of ANA testing in predicting the severity and progression of autoimmune diseases. The NCBI and MedRxiv have published numerous studies on ANA testing and its role in autoimmune disease diagnosis. Reimbursement policies and medical insurance coverage for ANA testing are key challenges that need to be addressed to increase market growth.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio